Pharma Focus Asia

Recursion Enters into Agreements to Acquire Cyclica and Valence

Tuesday, May 09, 2023

Recursion announced it has signed agreements to acquire Cyclica and Valence to bolster chemistry and generative AI capabilities.

The strategic acquisitions of Cyclica and Valence add industry-leading capabilities in digital chemistry, as well as machine-learning and artificial intelligence, combined with large-scale automated wet-laboratories and supercomputing capabilities, which enables to deploy the most complete, technology-enabled drug discovery solution in the biopharma industry.

The acquisition of Valence gives Recursion the opportunity to create a true centre of excellence for some of the most compelling AI/ML research in the world. With this newly integrated group housed in the Mila ecosystem, Recursion's team of researchers in AI and ML for drug discovery reaches a critical mass at a crucial time in the development of new AI algorithms for scientific discovery.

Cyclica and Recursion both believe in the value of industrializing drug discovery. Combining proteome-wide prediction of small molecule-target interactions into Recursion’s data universe will create one of the largest fit-for-purpose biological and chemical datasets in the drug discovery space.
 

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024ISPE Singapore Affiliate Conference & Exhibition 2024Rehab Expo 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024